CEFMAX
LOE Approachingcefmenoxime hydrochloride
NDAINJECTIONINJECTABLE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFMAX (cefmenoxime hydrochloride) is an injectable third-generation cephalosporin antibiotic approved in 1987. It is used to treat serious bacterial infections caused by susceptible organisms. The drug works by inhibiting bacterial cell wall synthesis, making it bactericidal.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating a mature, stable franchise with limited growth opportunities and likely consolidating team structure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEFMAX offers limited career growth potential given its mature lifecycle stage and approaching loss-of-exclusivity. Roles on this team typically focus on maximizing remaining patent value through operational efficiency and maintaining market share rather than innovation or expansion.
Brand ManagerCommercial Operations Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.